Loos Martin, Kleeff Jörg, Friess Helmut, Büchler Markus W
Department of General Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.
Curr Oncol Rep. 2008 May;10(3):212-9. doi: 10.1007/s11912-008-0033-8.
Pancreatic cancer is one of the most devastating human malignancies, with a mortality rate that almost equals its incidence rate. In cases of localized pancreatic cancer, surgical resection offers a chance for cure or at least prolonged survival. Adjuvant chemotherapy has been established as the standard of care; prospective, randomized controlled trials have demonstrated a distinct survival benefit of 5-fluorouracil/folinic acid or gemcitabine following surgical resection. More aggressive approaches, including neoadjuvant protocols, venous resections, and extended lymphadenectomy, have been suggested to improve long-term survival. However, based on the available data, there is either no benefit for these approaches or the evidence is not conclusive. Thus, further randomized controlled trials are needed to determine the role of novel therapy regimens in the treatment of pancreatic cancer.
胰腺癌是最具毁灭性的人类恶性肿瘤之一,其死亡率几乎等同于发病率。对于局限性胰腺癌病例,手术切除提供了治愈或至少延长生存期的机会。辅助化疗已成为标准治疗方法;前瞻性随机对照试验表明,手术切除后使用5-氟尿嘧啶/亚叶酸或吉西他滨可带来显著的生存获益。有人提出采用更积极的方法,包括新辅助方案、静脉切除和扩大淋巴结清扫术,以提高长期生存率。然而,根据现有数据,这些方法要么没有益处,要么证据不确凿。因此,需要进一步的随机对照试验来确定新治疗方案在胰腺癌治疗中的作用。